Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32985664.
- Also identified by DOI 10.1093/cid/ciaa1463 and PMC identifier 7543356.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.
Medical subject headings
- COVID-19
- Lymphohistiocytosis, Hemophagocytic